Nevro Net Profit Margin 2013-2022 | NVRO

Nevro net profit margin from 2013 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Nevro Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.39B $-0.14B -35.23%
2021-12-31 $0.39B $-0.13B -34.11%
2021-09-30 $0.39B $-0.11B -27.66%
2021-06-30 $0.41B $-0.07B -16.87%
2021-03-31 $0.36B $-0.09B -24.24%
2020-12-31 $0.36B $-0.08B -22.99%
2020-09-30 $0.37B $-0.09B -24.66%
2020-06-30 $0.36B $-0.10B -27.45%
2020-03-31 $0.40B $-0.09B -21.52%
2019-12-31 $0.39B $-0.10B -26.67%
2019-09-30 $0.38B $-0.10B -26.04%
2019-06-30 $0.38B $-0.09B -24.47%
2019-03-31 $0.38B $-0.08B -19.90%
2018-12-31 $0.39B $-0.05B -12.89%
2018-09-30 $0.38B $-0.04B -11.64%
2018-06-30 $0.36B $-0.04B -10.71%
2018-03-31 $0.35B $-0.04B -11.56%
2017-12-31 $0.33B $-0.04B -11.35%
2017-09-30 $0.30B $-0.04B -14.38%
2017-06-30 $0.28B $-0.04B -14.75%
2017-03-31 $0.26B $-0.04B -14.90%
2016-12-31 $0.23B $-0.03B -13.97%
2016-09-30 $0.19B $-0.04B -18.85%
2016-06-30 $0.15B $-0.05B -35.17%
2016-03-31 $0.10B $-0.06B -61.39%
2015-12-31 $0.07B $-0.07B -97.10%
2015-09-30 $0.05B $-0.06B -132.61%
2015-06-30 $0.04B $-0.05B -125.00%
2015-03-31 $0.04B $-0.04B -100.00%
2014-12-31 $0.03B $-0.03B -88.24%
2014-06-30 $0.02B $-0.02B -90.48%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.608B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.627B 21.80
Edwards Lifesciences (EW) United States $60.552B 42.53
Alcon (ALC) Switzerland $35.080B 30.59
STERIS (STE) Ireland $21.113B 26.67
Fresenius Medical Care AG KGaA (FMS) Germany $14.716B 13.22
Teleflex (TFX) United States $11.964B 19.12
Globus Medical (GMED) United States $5.873B 29.30
Penumbra (PEN) United States $4.736B 299.29
Integer Holdings (ITGR) United States $2.383B 18.51
Glaukos (GKOS) United States $2.256B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.313B 23.51
Paragon 28 (FNA) United States $1.281B 0.00
Artivion (AORT) United States $0.772B 83.52